Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Sovleplenib (HMPL-523) with Azacitidine in Elderly AML
NCT03483948Phase 1Terminated
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Oct 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sovleplenib in acute myeloid leukemia (AML), sponsored by Hutchison MediPharma (HMP). Primary endpoints: Adverse Event (AE) monitoring and Overall Response Rate up to 1 year. Started Oct 2018; status: terminated.
02
Drugs
sovleplenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03483948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03483948.